51³Ô¹ÏÍø

Tag - lecanemab

 
 

LECANEMAB

A team of researchers said they found a ¡°seed¡± that accelerates the amyloid beta accumulation process in the brain, naming it ¡°Peak 1 amyloid beta,¡± as seen in a mouse's brain.
51³Ô¹ÏÍø / Science & Health
Jul 21, 2026
Japan scientists identify clusters of protein believed to trigger Alzheimer¡¯s disease
The discovery of a new seed of the amyloid beta protein could lead to early-stage therapy for neurodegenerative disease, according to researchers.
Lecanemab and donanemab aim to slow the progression of the neurodegenerative disease by removing a protein called amyloid-beta from the brain, whose buildup is believed to contribute to the death of brain cells.
51³Ô¹ÏÍø / Science & Health
Apr 8, 2026
Less than 20% of patients in Japan interested in new Alzheimer¡¯s drugs received one
Many were ineligible or decided against taking the medications due to potential side effects and the high cost, a study has found.
Eisai's Alzheimer's drug Lecanemab, also known as Leqembi
51³Ô¹ÏÍø / Science & Health
Mar 25, 2026
Research team confirms safety of Alzheimer¡¯s drug Lecanemab
The research team examined data on the health status of 2,672 patients 28 weeks after the start of the treatment.
A scientist looks at scans of brains at the Memory Centre, part of the Department of Readaptation and Geriatrics at the University Hospital of Geneva (HUG), in 2023.
51³Ô¹ÏÍø / Science & Health / FOCUS
Sep 17, 2025
Japan¡¯s front-line researchers see bright path ahead for dementia treatment
Four scientists at the forefront of dementia research speak about what kind of future they envision for people with the condition.
The price of Alzheimer's drug Lecanemab, codeveloped by Japanese drugmaker Eisai and U.S. industry peer Biogen, will be lowered to ?97,277 for a 500-milligram bottle.
51³Ô¹ÏÍø / Science & Health
Aug 7, 2025
Japan approves price cut for Alzheimer¡¯s drug Lecanemab
The drug¡¯s price will be lowered to ?97,277 for a 500-milligram bottle starting on Nov. 1.
The health ministry is expected to cut the official price of lecanemab, an Alzheimer's drug codeveloped by Japanese drugmaker Eisai and Biogen of the United States, by up to 15% from the current level of about ?3 million per patient a year.
51³Ô¹ÏÍø / Science & Health
Jul 10, 2025
Japan to cut price of Alzheimer¡¯s drug lecanemab
The health ministry is expected to cut the official price of the drug by up to 15% from the current level of about ?3 million per patient a year.
Lecanemab was developed by drugmakers Eisai of Japan and Biogen of the United States.
51³Ô¹ÏÍø / Science & Health
Nov 15, 2024
European agency switches to recommending new Alzheimer¡¯s drug
The committee judged that the efficacy of lecanemab outweighs the risk for some patients.
A scientist looks at brain scans of a patient suffering from Alzheimer's disease in Geneva in 2023.
WORLD / Science & Health
Sep 21, 2024
Revolution or mirage? Controversy surrounds new Alzheimer¡¯s drugs
For defenders, the drugs represent a real chance to fight the disease. For detractors, they are a disappointment after a long line of costly failures.
51³Ô¹ÏÍø / Science & Health
Sep 25, 2023
As Japan OKs Alzheimer¡¯s drug, issue of side effects comes into focus
There are big challenges ahead for the use of lecanemab, particularly on how to control side effects such as brain swelling and bleeding.
51³Ô¹ÏÍø / Science & Health
Aug 21, 2023
Japanese ministry panel gives OK to Alzheimer¡¯s drug lecanemab
The panel¡¯s endorsement will be followed by official approval by the health minister in coming days.
Japan Times
WORLD / Science & Health / ANALYSIS
Sep 30, 2022
Eisai drug¡¯s trial success raises hope for Alzheimer¡¯s prevention
Scientists have already begun to debate whether the benefit of the drug is robust enough, but to many researchers, the findings suggest that preventing decline altogether is possible.

Longform

For many people, utility poles and power lines have become such a familiar part of Japan¡¯s landscape that they often go unnoticed.
Why Japan¡¯s utility poles won¡¯t be disappearing anytime soon

SUSTAINABLE 51³Ô¹ÏÍø